Title |
Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial
|
---|---|
Published in |
Psychopharmacology, December 2003
|
DOI | 10.1007/s00213-003-1686-5 |
Pubmed ID | |
Authors |
J. B. Deakin, S. Rahman, P. J. Nestor, J. R. Hodges, B. J. Sahakian |
Abstract |
Patients with frontal variant frontotemporal dementia (fvFTD) present with disinhibition, impulsiveness, apathy, altered appetite and stereotypic behaviors. A non-randomized clinical trial found improvement in these symptoms after treatment with a selective serotonin reuptake inhibitor (SSRI). |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 50% |
France | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 33% |
Practitioners (doctors, other healthcare professionals) | 2 | 33% |
Scientists | 1 | 17% |
Unknown | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
United States | 1 | <1% |
Denmark | 1 | <1% |
Unknown | 141 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 24 | 17% |
Researcher | 22 | 15% |
Student > Ph. D. Student | 17 | 12% |
Student > Bachelor | 16 | 11% |
Other | 14 | 10% |
Other | 28 | 19% |
Unknown | 23 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 37 | 26% |
Psychology | 36 | 25% |
Neuroscience | 22 | 15% |
Agricultural and Biological Sciences | 9 | 6% |
Social Sciences | 4 | 3% |
Other | 6 | 4% |
Unknown | 30 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2023.
All research outputs
#8,439,138
of 25,402,889 outputs
Outputs from Psychopharmacology
#2,220
of 5,324 outputs
Outputs of similar age
#36,159
of 142,971 outputs
Outputs of similar age from Psychopharmacology
#22
of 44 outputs
Altmetric has tracked 25,402,889 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 5,324 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 142,971 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.